BioStem Technologies's total inventories for the quarter that ended in Sep. 2025 was $2.7 Mil. BioStem Technologies's average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Sep. 2025 was $2.3 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioStem Technologies's Net-Net Working Capital per share for the quarter that ended in Sep. 2025 was $1.86.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioStem Technologies's Days Inventory for the
three
months ended in Sep. 2025 was 172.53.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioStem Technologies's Inventory Turnover for the quarter that ended in Sep. 2025 was 0.53.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioStem Technologies's Inventory-to-Revenue for the quarter that ended in Sep. 2025 was 0.22.
BioStem Technologies (OTCPK:BSEM) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
BioStem Technologies's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioStem Technologies's Inventory to Revenue for the quarter that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
BioStem Technologies Total Inventories Related Terms
BioStem Technologies Total Inventories Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
BioStem Technologies (BSEM) has a Total Inventories of $2.7 Mil as of Sep. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioStem Technologies and its competitors.
Is BioStem Technologies' Total Inventories too high?
BioStem Technologies' current Total Inventories is $2.7 Mil. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Total Inventories compare to TCRX and BYSI?
BioStem Technologies' Total Inventories of $2.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioStem Technologies and its competitors. BioStem Technologies's current Total Inventories is $2.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.50 — trading 97.5% below its estimated fair value. The current Total Inventories is $2.7 Mil. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Total Inventories is $2.7 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.50 is trading 97.5% below its estimated GF Value™ of $139.96.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
Total Inventories: $2.7 Mil
GF Value™: $139.96 vs. price of $3.50 (97.5% below fair value)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
